Less Haste, More Speed, More Science: Lessons to be Learned from COVID-19 Studies.

With respect to other large anti–GM-CSF trials, lenzilumab (a GM-CSF–neutralizing monoclonal antibody) was associated with improved Day 28 survival without invasive mechanical ventilation, though the perhaps more pertinent outcome of overall mortality failed to reach significance (10% vs. 14% placebo; P = 0.24) ( 10 ).

also in 4,113 other papers